| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vitro |
α-Mangostin (α-Mangostin) suppresses IDH1-R132H but not IDH1. IDH1-R132H is inhibited by α-Mangostin (α-Mangostin). According to studies, the strongest core flipped structure is seen in α-Mangostin (α-Mangostin). α-Mangostin (α-Mangostin) preferentially stimulates the demethylation of trimethylated lysine residues in histone H3 and 5-methylcellulose (5mC) in IDH1 (+/R132H) MCF10A cells [1]. Cell proliferation was markedly and dose-dependently inhibited in cells treated with α-mangostin. Additionally, α-Mangosteen raises mitochondrial caspase-9, mitochondrial caspase-3, mitochondrial poly(ADP-ribose) polymerase (PARP), and pigmentogen Bax levels [2]. α-Mangostin (α-Mangostin) notably reduces fotoThe production of reactive oxygen species (ROS) and malondialdehyde (MDA) caused by light is inhibited by α-Mangostin (α-Mangostin) at 200 μM H2O2[3].
|
|---|---|
| ln Vivo |
By decreasing p53 expression in comparison to TAA_DMSO therapy, α-Mangostin (α-Mangostin) lowers the risk of liver fibrosis. Compared to DMSO alone, the therapy with α-Mangostin resulted in lower serum levels of the liver enzymes AST and ALT [4].
|
| Toxicity/Toxicokinetics |
Interactions
Membrane integrity alterations and inflammation play a crucial role in cardiovascular injury. This study investigated the beneficial effects of exogenous α-retropine on β-adrenergic catecholamine-induced cardiovascular toxicity, focusing particularly on the expression of membrane ATPases, lysosomal hydrolases, and inflammatory mediators TNF-α and cyclooxygenase-2 (COX-2) in albino rats. Two days after induction with isoproterenol (150 mg/kg body weight, intraperitoneal injection), the activities of serum and cardiac lysosomal hydrolases (β-D-glucuronidase, β-D-galactosidase, β-DN-acetylglucosidase, acid phosphatase, and cathepsin D) were significantly increased. Significantly elevated sodium and calcium levels and decreased potassium levels were observed in the hearts of rats treated with isoproterenol (ISO), along with abnormal activity of membrane-bound phosphatases (Na(+)-K(+) ATPase, Ca(2+) ATPase, and Mg(2+) ATPase). Western blotting was used to detect the expression of TNF-α and COX-2 in the heart. Results showed that the expression of TNF-α and COX-2 was significantly elevated in the hearts of ISO-poisoned rats. Pre-oral administration of α-mangosteen (200 mg/kg body weight) for 8 days significantly alleviated these abnormalities and restored TNF-α and COX-2 levels to near-normal levels, showing a significant difference compared to the ISO-poisoned group. In summary, α-mangosteen maintains the integrity of cardiomyocyte membranes and reduces the abnormal expression of TNF-α and COX-2 by effectively alleviating ISO-induced oxidative stress and cell damage. The restoration of normal cellular status confirms the cytoprotective effect of α-mangosteen. Cisplatin (CDDP) is a chemotherapeutic drug that can cause nephrotoxicity associated with oxidative/nitrosogenic stress. α-mangosteen (α-M) is a flavonoid compound extracted from mangosteen and possesses antioxidant and anti-inflammatory properties. This study aimed to evaluate the renal protective effect of α-M against CDDP-induced nephrotoxicity. α-M (12.5 mg/kg/day, by gavage) was administered continuously for 10 days (7 days before and 3 days after CDDP injection). On day 7, rats received a single injection of CDDP (7.5 mg/kg, intraperitoneal injection); rats were sacrificed 3 days later. α-M reduced renal dysfunction, structural damage, oxidative/nitrosation stress, decreased catalase expression, and increased levels of tumor necrosis factor α and transforming growth factor β mRNA. In summary, the renal protective effect of α-M against cisplatin-induced nephrotoxicity was associated with the reduction of oxidative/nitrosation stress, inflammation and fibrosis markers, and the maintenance of catalase activity. α-Daucusin, isolated from the bark of Garcinia mangostana L., was active against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), with minimum inhibitory concentrations (MICs) of 6.25 μg/mL and 6.25–12.5 μg/mL, respectively. Our research indicates that alpha-retropine has a synergistic effect with gentamicin (GM) against vancomycin-resistant enterococci (VRE), and with vancomycin hydrochloride (VCM) against methicillin-resistant Staphylococcus aureus (MRSA). Further studies have shown that alpha-retropine also exhibits partial synergistic effects with commercially available antibiotics such as ampicillin and minocycline. These findings suggest that alpha-retropine, used alone or in combination with gentamicin, may be helpful in controlling VRE and MRSA infections, and its combination with vancomycin may also be effective. |
| References |
|
| Additional Infomation |
α-Xanthocyanin belongs to the xanthones class of compounds with the structure 9H-xanthones, substituted with hydroxyl groups at positions 1, 3, and 6, a methoxy group at position 7, a carbonyl group at position 9, and isopentenyl groups at positions 2 and 8. It was isolated from the stem of hawthorn (Cratoxylum cochinchinense) and possesses antioxidant, antibacterial, and antitumor activities. It can be used as an antitumor agent, antibacterial agent, antioxidant, and plant metabolite. It belongs to the xanthones, phenols, and aromatic ethers.
Xanthocyanin is a plant/plant extract used in certain over-the-counter (OTC) products. It is not an approved drug. α-Xanthocyanin has been reported to exist in Garcinia cowa, Garcinia merguensis, and other organisms with relevant data. See also: Garcinia mangostana pericarp (partial). Therapeutic Uses Xanthones; Protein kinase inhibitors /Experimental Therapy/Mangosteen has a long history of medicinal use in Chinese and Ayurvedic medicine. Recently, α-dextrin, a compound isolated from mangosteen pericarp, has been shown to induce the death of various cancer cells in vitro. This prompted us to investigate the anti-tumor growth and anti-metastatic activity of α-dextrin in a mouse xenograft model of metastatic breast cancer with a p53 mutation. This p53 mutation induces a metastatic spectrum similar to that of human breast cancer. After inoculating homologous BALB/c mice with metastatic BJMC3879luc2 cells to induce breast tumors, α-dextrin was administered using a micro-osmotic pump at doses of 0, 10, and 20 mg/kg/day, respectively, and histopathological examination was performed. In vitro experiments were also conducted to explore the anti-tumor mechanism of α-dextrin. The results showed that, compared with the control group, the in vivo survival rate of the 20 mg/kg/day α-dextrin group was significantly improved, and the tumor volume and the number of lymph node metastases were significantly reduced. The 20 mg/kg/day α-dextrin group also showed a significant increase in apoptosis levels in mouse mammary tumors, accompanied by increased expression of active caspase-3 and caspase-9. Furthermore, this dose group also showed decreased microvessel density and a reduced number of dilated lymphatic vessels containing intraluminal tumor cells in breast cancer tissue. In vitro experiments demonstrated that α-dextrin can induce mitochondrial-mediated apoptosis and inhibit the G1 and S phases of the cell cycle. Since Akt phosphorylation activation plays a central role in various carcinogenic processes, including cell proliferation, anti-apoptotic cell death, angiogenesis, and metastasis, we also investigated the effects of α-dextrin on Akt phosphorylation levels in vitro and in vivo. Quantitative analysis and immunohistochemical results showed that α-retropine significantly reduced the level of phosphorylated Akt-threonine 308 (Thr308) in breast cancer cell cultures and in vivo breast cancer tissues, but had no effect on the level of serine 473 (Ser473). Since lymph node metastasis is the most important prognostic factor for breast cancer patients, the anti-metastatic activity of α-retropine detected in p53-mutant breast cancer in this study may have specific clinical application value. Furthermore, α-retropine may have chemopreventive effects and/or may serve as adjuvant therapy or a complementary alternative to breast cancer treatment. /Experimental Therapy/ This study aimed to test the activity of α-retropine against Candida albicans (the most important microorganism causing oral candidiasis) and compare its activity with clotrimazole and nystatin. The results showed that α-retropine was effective against Candida albicans, with a minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MFC) of 1000 and 2000 μg/mL, respectively. Alpha-retropine exhibits superior antifungal activity against Candida albicans compared to clotrimazole and nystatin. The cytotoxicity of α-retropine was determined, and a concentration of 4000 μg/mL was found to be non-toxic to human gingival fibroblasts within 480 minutes. Alpha-retropine's potent antifungal activity and low toxicity make it a promising drug for the treatment of oral candidiasis. /Experimental Therapy/ Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of β-sheet-rich amyloid oligomers or fibrils, which are associated with cytotoxicity in the brain. Inhibiting Aβ accumulation may be a feasible therapeutic strategy to slow and/or halt the progression of AD. This article reports that the mangosteen polyphenol xanthones derivative α-dextrin (aM) can attenuate, in a concentration-dependent manner, the neurotoxicity induced by Aβ-(1-40) or Aβ-(1-42) oligomers (EC50 values of 3.89 nM and 4.14 nM, respectively) in primary rat cerebral cortical neurons, manifested as decreased cell viability and impaired neurite growth. Molecular docking and kinetic simulations suggest that aM may bind to Aβ and stabilize its α-helical conformation. Western blot analysis using oligomer-specific antibodies revealed that aM can directly dissociate Aβ-(1-40) and Aβ-(1-42) oligomers. Thioflavin T fluorescence assays and electron microscopy further confirmed that aM can inhibit fibril formation and disrupt existing fibrils. In summary, these results indicate that aM can inhibit and dissociate Aβ aggregation, which may help alleviate Aβ oligomer-induced neurotoxicity. Therefore, aM may be a highly promising candidate drug for the treatment of Alzheimer's disease (AD)... |
| Molecular Formula |
C24H26O6
|
|---|---|
| Molecular Weight |
410.4596
|
| Exact Mass |
410.172
|
| Elemental Analysis |
C, 70.23; H, 6.38; O, 23.39
|
| CAS # |
6147-11-1
|
| Related CAS # |
beta-Mangostin; 20931-37-7
|
| PubChem CID |
5281650
|
| Appearance |
Yellow solid solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
640.1±55.0 °C at 760 mmHg
|
| Melting Point |
182ºC
|
| Flash Point |
220.3±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.624
|
| LogP |
5.45
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
677
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C([H])=C(C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])=C(C=2C(C2=C1C([H])=C(C(=C2C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])OC([H])([H])[H])O[H])=O)O[H])O[H]
|
| InChi Key |
GNRIZKKCNOBBMO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H26O6/c1-12(2)6-8-14-16(25)10-19-21(22(14)27)23(28)20-15(9-7-13(3)4)24(29-5)17(26)11-18(20)30-19/h6-7,10-11,25-27H,8-9H2,1-5H3
|
| Chemical Name |
1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one
|
| Synonyms |
NSC 27593; NSC 139154; NSC 30552; Alpha-Mangostin; NSC27593; NSC139154; NSC30552
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~267.99 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (6.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4363 mL | 12.1815 mL | 24.3629 mL | |
| 5 mM | 0.4873 mL | 2.4363 mL | 4.8726 mL | |
| 10 mM | 0.2436 mL | 1.2181 mL | 2.4363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06039774 | Recruiting | Drug: Placebo Drug: α-Mangostin Hydrogel Film With Chitosan Alginate Base |
Recurrent Aphthous Stomatitis | Universitas Padjadjaran | December 4, 2023 | Phase 2 |